title: The prognostic and predictive value of the lymphocyte to monocyte ratio in luminal-type breast cancer patients treated with CEF chemotherapy.
abstract: Several reports have suggested that peripheral blood-based parameters are associated with host immunity response, which is an essential component of the pathogenesis and progression of cancer. The purpose of the present study was to identify the prognostic significance of various peripheral blood-based biomarkers and to determine the optimal cut-off value suitable for luminal breast cancer patients. We found that lymphocyte-to-monocyte ratio (LMR) was significant prognostic predictors. And the patients with a CEF regimen and LMR ratio ≥ 5.2 gained a good prognosis. This study suggested that the LMR could be regarded as an independent prognostic factor in luminal breast cancer patients. The elevated LMR level also had enhanced 5-fluorouracil sensitivity in luminal breast cancer patients.
authors.affiliation: Department of Cancer Molecular and Biology, Cancer Institute, Harbin Medical University, Harbin, China.|Department of Cancer Molecular and Biology, Heilongjiang Academy of Medical Sciences, Harbin, China.
authors.forename: Hongfei
authors.initials: H
authors.lastname: Ji
authors.affiliation: Department of Medical Oncology, Tumor Hospital of Harbin Medical University, Harbin, China.
authors.forename: Qijia
authors.initials: Q
authors.lastname: Xuan
authors.affiliation: Department of Cancer Molecular and Biology, Cancer Institute, Harbin Medical University, Harbin, China.|Department of Cancer Molecular and Biology, Heilongjiang Academy of Medical Sciences, Harbin, China.
authors.forename: Caichuan
authors.initials: C
authors.lastname: Yan
authors.affiliation: Department of Medical Oncology, Tumor Hospital of Harbin Medical University, Harbin, China.
authors.forename: Tao
authors.initials: T
authors.lastname: Liu
authors.affiliation: Department of Pathology, Tumor Hospital of Harbin Medical University, Harbin, China.
authors.forename: Abiyasi
authors.initials: A
authors.lastname: Nanding
authors.affiliation: Department of Cancer Molecular and Biology, Cancer Institute, Harbin Medical University, Harbin, China.|Department of Medical Oncology, Tumor Hospital of Harbin Medical University, Harbin, China.|Department of Cancer Molecular and Biology, Heilongjiang Academy of Medical Sciences, Harbin, China.
authors.forename: Qingyuan
authors.initials: Q
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy*; D045744:Cell Line, Tumor; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D015251:Epirubicin / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D018655:Lymphocyte Count; D008214:Lymphocytes / Q000166:cytology*; D061986:MCF-7 Cells; D008875:Middle Aged; D009000:Monocytes / Q000166:cytology*; D011379:Prognosis; D043823:Taxoids / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D003561:Cytarabine; D015251:Epirubicin; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil
keywords: 5-fluorouracil; breast cancer; lymphocyte-to-monocyte ratio; prognostic factor